Phase 1 — Early testing in a small group of people (usually 20–80) to evaluate safety, determine safe dosage, and identify side effects.
Trial locations(5 sites)
United States
Stanford Cancer Institute, Stanford, California Washington University School of Medicine, St Louis, Missouri Memorial Sloan Kettering Cancer Center, New York, New York Sarah Cannon Research Institute, Nashville, Tennessee Canada
British Columbia Cancer Agency, Vancouver, British Columbia